Provided by Tiger Trade Technology Pte. Ltd.

Protalix BioTherapeutics

2.73
+0.06002.25%
Post-market: 2.70-0.0300-1.10%19:40 EDT
Volume:782.52K
Turnover:2.11M
Market Cap:219.55M
PE:11.55
High:2.74
Open:2.66
Low:2.64
Close:2.67
52wk High:3.19
52wk Low:1.60
Shares:80.42M
Float Shares:76.54M
Volume Ratio:1.04
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2364
EPS(LYR):-0.0841
ROE:31.23%
ROA:15.42%
PB:3.07
PE(LYR):-32.47

Loading ...

Protalix BioTherapeutics Price Target Maintained with a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 09

Protalix CFO to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

3 Promising Penny Stocks With Over $50M Market Cap

Simply Wall St.
·
Aug 26

Pelthos Therapeutics Q2 Revenue Rises on Zelsuvmi Adoption

Reuters
·
Aug 13

Israel's MediWound Beats Q2 Revenue Estimates, Reaffirms 2026 Guidance

Reuters
·
Aug 13

Protalix (PLX) Stock Profit Swing Sharpens Focus On Elfabrio Reliance

Simply Wall St.
·
Aug 13

Protalix Publishes Corporate Presentation Highlighting Elfabrio Commercialization and PRX-115 Phase 2 Gout Study

Reuters
·
Aug 12

Protalix BioTherapeutics Q2 Pretax Profit USD 4.86 Million

Reuters
·
Aug 12

Israel's Protalix Q2 Revenue Rises on Elfabrio Sales, Reiterates 2026 Outlook

Reuters
·
Aug 12

Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate

Benzinga Earnings
·
Aug 12

Protalix Swings to Q2 Profit of USD 3.8 Million; Revenue from Selling Goods Rises 28.5% to USD 19.8 Million

Reuters
·
Aug 12

Press Release: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Dow Jones
·
Aug 12

Protalix BioTherapeutics to Report Q2 Results, Host Conference Call and Webcast

Reuters
·
Aug 05

Protalix Biotherapeutics Shareholders Approved Amended 2006 Stock Incentive Plan Share Increase to 20,975,171 Shares

Reuters
·
Jun 26

Barclays Keeps Their Hold Rating on PLUXEE N.V. (PLX)

TIPRANKS
·
Jun 19

Protalix BioTherapeutics posts corporate presentation outlining rare-disease portfolio, PRX-115 development plans

Reuters
·
May 13

Protalix BioTherapeutics Q1 EPS USD 0.23

Reuters
·
May 13

Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate

Benzinga Earnings
·
May 13

Israel's Protalix Q1 revenue surges on Chiesi milestone

Reuters
·
May 13

Protalix Q1 FY26 swings to net income of $18.32 million; revenue more than doubled to $33.75 million

Reuters
·
May 13